Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.
about
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferaseThiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in CaucasiansEnhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activityPharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UseDetection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysisThe clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatmentHuman thiopurine methyltransferase activity varies with red blood cell ageThiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activityThioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.Therapeutic drug monitoring of antimetabolic cytotoxic drugs.Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine modelThiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseSafety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis.The accumulation of mercaptopurine metabolites in age fractionated red blood cells.Pharmacogenetics in clinical practice: considerations for testing.Recent advances in the pharmacogenomics of thiopurine methyltransferase.Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population.Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?Inherited genetic variation in childhood acute lymphoblastic leukemia.Guidelines for the management of inflammatory bowel disease in adults.Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug eventsIntracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel diseaseCost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.Overview of the pharmacoeconomics of pharmacogenetics.Nomenclature for alleles of the thiopurine methyltransferase gene.Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas.Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity.Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?Developmental pharmacogenomics.TPMT in the treatment of Crohn's disease with azathioprine.Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A/*3C Polymorphisms in a Patient with Pediatric Leukemia and the Effect of Steroid Therapy.6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicityAssessing the cost-effectiveness of pharmacogenomics.Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine.Frequency of thiopurine S-methyltransferase (TPMT) alleles in southeast Iranian population.An improved HPLC method for the quantitation of 6-mercaptopurine and its metabolites in red blood cells.Azathioprine-related myelosuppression in a patient homozygous for TPMT*3A.
P2860
Q24563229-E1A9D8C6-E8FF-436C-AD39-BD798CE97FE2Q24676047-79A5F4FF-0543-4FA1-9440-522E04ECB43FQ24682894-C4EC76C7-6FF0-432D-95EF-8E269EAE4285Q28068930-C8918DC5-DD01-41E1-80F7-FF2B90EE1BCBQ28280113-BE438DF8-D7AF-4570-8715-4BEE9002B9ECQ28295707-AD6D1295-36C9-42D3-B293-49C9839E2A0EQ28365897-024971B3-C102-424D-90D9-5E088697C4B6Q33394134-1F6D3B7B-3E7D-4EB4-A745-D246F90C7E0AQ33418418-3216B5D4-C56C-409A-80D4-9AB5ECBF5468Q33503259-DEC55382-2F4A-4EC6-8CE7-C1DE47632D39Q33586713-8D534DAB-BECE-4FCC-AA27-02E8A5755267Q33603164-25935AF4-11B1-4526-BB61-E27DD9E3A719Q33674158-CA374501-0834-492C-832E-602021DC2EAFQ33890504-0DD215D8-AC57-444E-92C8-D1219788D2DBQ34347394-89EEF108-C9C6-4096-9829-E24144FB547CQ34499056-A1C2BEC6-5C3F-40EE-8F31-64620E55BA31Q34574036-DD9360F4-0BAD-404A-AF72-D28E4558BCCBQ34793050-B6051D1A-2A46-48E2-8117-1C8CF1E7F9FCQ35135954-264465A5-E1E5-461C-A48D-BC104F045AF6Q35784497-5CE6E2A4-7B82-468A-AF8C-98C431BA035DQ35790559-D038314A-A8B5-4041-8CD3-740FC40BA939Q35988128-F233544F-02FB-4D1A-BDEA-1214B52EFECCQ36081628-DBF4E77F-3121-48F8-A49B-FE7B04C37CF8Q36402208-79FDB1C7-14E6-4F01-B244-44F2D33F895BQ36443655-8391CA48-F7DF-4AF0-98BA-809EA12C25F4Q36555938-A8C18687-EF30-407D-818A-276A54C4737BQ36690248-5DCB8A5A-CAA6-4E3A-822A-307F78C4CE0AQ37056505-2A3BE01B-555E-4F12-BB08-654852613786Q37236431-9F9889E3-3017-45E5-BEC4-3F7FCDBB22FBQ37378665-34865023-6488-4F93-B5CC-A0984C49DD21Q37688050-177FA62A-1B1D-4F52-84AA-2674C2C890C3Q37841723-C4498475-70EB-465D-85BB-E57C1CCA85FAQ41762842-7D4243C3-C9A1-457E-93C1-BE0FFF06EFDFQ42129264-F647386D-00D7-4098-975C-5EDA5533C066Q42255552-D2665F1A-D252-4B9E-984E-4EF9E7FFF23BQ42582690-2EC64B70-ADA3-48CF-BDEE-A762FDA44534Q42758200-25E9B59C-EB1D-4BD8-B52E-8EC0E5917420Q43090959-0AEA972B-355B-44AD-89EC-F8F5D99723A5Q44859810-B4CB75FC-66A9-4625-92F1-D26467728F6BQ48837974-395AF00B-74C3-4E50-862B-556B1E058375
P2860
Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Congenital thiopurine methyltr ...... acute lymphoblastic leukaemia.
@ast
Congenital thiopurine methyltr ...... acute lymphoblastic leukaemia.
@en
type
label
Congenital thiopurine methyltr ...... acute lymphoblastic leukaemia.
@ast
Congenital thiopurine methyltr ...... acute lymphoblastic leukaemia.
@en
prefLabel
Congenital thiopurine methyltr ...... acute lymphoblastic leukaemia.
@ast
Congenital thiopurine methyltr ...... acute lymphoblastic leukaemia.
@en
P2093
P2860
P356
P1476
Congenital thiopurine methyltr ...... acute lymphoblastic leukaemia.
@en
P2093
P2860
P304
P356
10.1136/ADC.69.5.577
P407
P577
1993-11-01T00:00:00Z